Pharvaris (NASDAQ:PHVS) Shares Sold by Sphera Funds Management LTD.

Sphera Funds Management LTD. decreased its position in Pharvaris (NASDAQ:PHVS - Free Report) by 11.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 388,183 shares of the company's stock after selling 51,109 shares during the period. Pharvaris makes up about 1.3% of Sphera Funds Management LTD.'s portfolio, making the stock its 24th biggest holding. Sphera Funds Management LTD. owned about 0.74% of Pharvaris worth $7,441,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. raised its stake in Pharvaris by 1,125.3% in the 4th quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company's stock worth $59,000 after acquiring an additional 2,847 shares during the last quarter. Cubist Systematic Strategies LLC purchased a new position in Pharvaris in the 4th quarter worth $64,000. Barclays PLC purchased a new position in Pharvaris in the 3rd quarter worth $106,000. KLP Kapitalforvaltning AS purchased a new position in Pharvaris in the 4th quarter worth $111,000. Finally, Point72 Asset Management L.P. purchased a new position in shares of Pharvaris during the 4th quarter valued at about $152,000.

Pharvaris Trading Up 0.8%

Shares of NASDAQ PHVS traded up $0.13 during trading on Monday, reaching $16.69. 39,946 shares of the company traded hands, compared to its average volume of 74,165. The firm's fifty day simple moving average is $15.38 and its 200 day simple moving average is $17.58. The stock has a market cap of $872.72 million, a P/E ratio of -5.96 and a beta of -2.85. Pharvaris has a 12-month low of $11.51 and a 12-month high of $25.50.

Pharvaris (NASDAQ:PHVS - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.89) earnings per share for the quarter, missing analysts' consensus estimates of ($0.80) by ($0.09). As a group, research analysts expect that Pharvaris will post -2.71 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on PHVS. Cantor Fitzgerald reduced their price objective on Pharvaris from $28.00 to $25.00 and set an "overweight" rating for the company in a research note on Wednesday, May 14th. JMP Securities lifted their price objective on Pharvaris from $46.00 to $55.00 and gave the company a "market outperform" rating in a research note on Friday, January 31st.

Pharvaris Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.